Navigation Links
Adheron Therapeutics Announces Favorable Phase 1 Clinical Trial Results
Date:1/8/2014

SAN FRANCISCO, Jan. 8, 2014 /PRNewswire/ -- Adheron Therapeutics, a biotechnology company which focuses on leveraging pioneering technology that disrupts cell adhesion to treat a variety of diseases, announced the completion of the company's Phase 1 clinical trial for its leading Cad-11 inhibitor SDP051.  Cad-11 acts as a key mediator of joint destruction in rheumatoid arthritis, and is also an important contributor to fibrotic pathology. These are disease pathways that Adheron Therapeutics is particularly interested in pursuing.

SDP051 is a humanized monoclonal antibody to Cadherin-11, which acts as an "adhesive" between cells. Changes in Cad-11 interactions can induce cells to produce proteins that influence the cellular environment. The recently completed SDP051 trial was designed to assess the safety and tolerability of an escalating single dose of the compound in healthy volunteers who received SDP051 or placebo. The trial also assessed the pharmacokinetic properties of the protein in vivo.

Results from the Phase 1 trial show that SDP051 is safe and well-tolerated at doses up to 10 mg/kg per day with no evidence of significant side effects.

"The results from this trial meet and even exceed our expectations for safety, and provide evidence for an excellent dosing schedule," said Hari Kumar, CEO of Adheron Therapeutics. "The favorable profile lays the foundation for us to evaluate once monthly dosing in a Phase 2 trial, which we expect to start in 2015."

About Cad-11

Cadherin-11 (Cad-11) is a surface protein expressed on fibroblasts in the skin and lungs, and fibroblast-like synoviocytes (FLS) in the joints. Cad-11 acts as an "adhesive" between cells, and changes in Cad-11 interactions can induce the cells to produce proteins that influence the cellular environment. Research completed in the laboratory of Michael Brenner, MD, at
'/>"/>

SOURCE Adheron Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Adheron Therapeutics Names New Senior Leadership
2. Todd Rider Joins Draper to Continue Antiviral Therapeutics Development
3. Arcturus Therapeutics, Inc. to Present at the Biotech Showcase 2014
4. Orexigen Therapeutics to Present at the J.P. Morgan 2014 Healthcare Conference
5. Agilis Biotherapeutics and Intrexon to Pursue Transformative Therapies for Rare Genetic Disease
6. Collaborations, FDA Approvals, Appointments, Patents, and Stock Movements - Research Report on Aetna, United Therapeutics, Perrigo, Arena Pharmaceuticals, and Keryx Biopharmaceuticals
7. PTC Therapeutics Added to NASDAQ Biotechnology Index
8. Lightlake Therapeutics Inc. Chief Executive Officer Letter to Shareholders
9. Moderna Therapeutics Appoints Theo Melas-Kyriazi to Board of Directors
10. Abeona Therapeutics Closes $750,000 in Seed Round to Develop Therapies for Children Suffering from Rare Sanfilippo Diseases
11. BiOptix Continues Support of Antibody Engineering & Therapeutics Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 Date: Friday, April 11, 2014 ... Country Club, 1360 Almshouse Road, Warrington, Pa. , ... solely dedicated to finding a cure for hepatitis B and ... host its annual Crystal Ball on Friday, April 11 at ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging ... to serve the wound care market. , Free report ... was restructured with a seasoned management team and Board, ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors ... Plague.” In this time period, doctors did not know that ... to the death of vulnerable patients. In the same way, ... may be unwittingly transmitting herpes viruses to their patients. The ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... BOSTON, Mass., June 4 Experts with ... PAREXEL,International Corporation (Nasdaq: PRXL ), a ... 2008 BIO,International Convention to be held June ... in San Diego, California. PAREXEL has worked ...
... do the French get away with a clean bill of ... The answer to the so-called "French paradox" may be found ... doses of resveratrol, a natural constituent of grapes, pomegranates, red ... an international team of researchers. , Writing this week (June ...
... Mass., June 3 Xceed Molecular, a ... analysis,systems, has granted Gen-Probe Incorporated (Nasdaq: ... to use Xceed,s novel Flow-Thru Chip,technology. Gen-Probe ... its,next-generation multiplexed molecular-diagnostics products. Gen-Probe is a,global ...
Cached Biology Technology:PAREXEL Product Development and Regulatory Experts to Attend the 2008 BIO International Convention 2PAREXEL Product Development and Regulatory Experts to Attend the 2008 BIO International Convention 3PAREXEL Product Development and Regulatory Experts to Attend the 2008 BIO International Convention 4Agent in red wine found to keep hearts young 2Agent in red wine found to keep hearts young 3Xceed Molecular Grants Gen-Probe License to Xceed's Flow-Thru Chip(R) Technology for Multiplex Molecular Diagnostics 2
(Date:4/24/2014)... WEST LAFAYETTE, Ind. - Purdue and West Virginia University ... the golden eagle, providing a bird,s-eye view of eagle ... , Their study calls into question long-held assumptions ... not be as sensitive to ultraviolet light as previously ... have a sharper sense of smell than researchers realized. ...
(Date:4/24/2014)... published in the Scientific Reports journal. , CSIC ... joint centre of CSIC and Pompeu Fabra University-UPF), explains: "When ... we saw that it did not match with the DNA ... the complete genome and to make a functional interpretation in ... Louis XVI". , The functional genome analysis was based ...
(Date:4/24/2014)... N.C. -- A new study representing the largest study of ... broader diets have better self-control. , Published this week in ... , the study is part of a long history of ... some species able to do things like make and use ... others aren,t? , Until now, most studies of animal ...
Breaking Biology News(10 mins):Genome yields insights into golden eagle vision, smell 2The blood preserved in the pumpkin did not belong to Louis XVI 2Animals with bigger brains, broader diets have better self control 2Animals with bigger brains, broader diets have better self control 3
... detection techniques developed at the University, the team mapped ... and developed a model of their likely distribution as ... action is needed. University of Canberra professor in ... found foxes are widespread in northern and eastern Tasmania ...
... University of Southampton has shown that copper can ... to the increasing number of antibiotic-resistant infections worldwide. ... largely responsible for the development of antibiotic-resistance, which ... healthcare-associated infections (HCAIs). The newly-published paper, which ...
... Institution are rolling out results from the new Airborne ... at the American Geophysical Union (AGU) meetings in San ... uncovering a previously invisible ecological world. To watch a ... the world in a whole new way, click here. ...
Cached Biology News:Fox invasion threatens wave of extinction, UC research finds 2New study shows how copper restricts the spread of global antibiotic-resistant infections 2Carnegie debuts revolutionary biosphere mapping capability at AGU 2Carnegie debuts revolutionary biosphere mapping capability at AGU 3
Porcine Serum Available Anticoagulants: N-02: Citrate N-04: Heparin (Na) N-06: K2EDTA N-08: Potassium Oxalate N-10: EDTA (Na) N-03: Alsevers N-05: ACD N-07: CPD N-09: K3EDTA N-11...
Recombinant Viral CCI/Fc Chimera, CF...
... • Guinea Pig serum is collected from fasted ... N-02: Citrate N-04: Heparin (Na) ... Oxalate N-10: EDTA (Na) N-03: ... CPD N-09: K3EDTA N-11: ...
GENOMIPHI V2 DNA AMP KIT 25RXN, 1 EA. Category: Genomics DNA Amplification....
Biology Products: